Aung Naing

23.4k total citations · 3 hit papers
483 papers, 12.5k citations indexed

About

Aung Naing is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Aung Naing has authored 483 papers receiving a total of 12.5k indexed citations (citations by other indexed papers that have themselves been cited), including 296 papers in Oncology, 142 papers in Molecular Biology and 132 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Aung Naing's work include Cancer Immunotherapy and Biomarkers (131 papers), Cancer Genomics and Diagnostics (92 papers) and Lung Cancer Treatments and Mutations (64 papers). Aung Naing is often cited by papers focused on Cancer Immunotherapy and Biomarkers (131 papers), Cancer Genomics and Diagnostics (92 papers) and Lung Cancer Treatments and Mutations (64 papers). Aung Naing collaborates with scholars based in United States, United Kingdom and Spain. Aung Naing's co-authors include David S. Hong, Razelle Kurzrock, Siqing Fu, Apostolia M. Tsimberidou, Jennifer J. Wheler, Gerald S. Falchook, Filip Jankú, Sarina A. Piha‐Paul, Funda Meric‐Bernstam and Vivek Subbiah and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Aung Naing

466 papers receiving 12.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

2021 257 citations Giuseppe Curigliano, Hans Gelderblom et al. Clinical Cancer Research profile →
Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?

2014 255 citations Chad Tang, Erminia Massarelli et al. profile →
Applications and clinical trial landscape using Toll-like receptor agonists to reduce the toll of cancer

2023 105 citations Aung Naing et al. profile →

Peers

Countries citing papers authored by Aung Naing

Since Specialization

Citations

This map shows the geographic impact of Aung Naing's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aung Naing with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aung Naing more than expected).

Fields of papers citing papers by Aung Naing

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aung Naing. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aung Naing. The network helps show where Aung Naing may publish in the future.

Co-authorship network of co-authors of Aung Naing

This figure shows the co-authorship network connecting the top 25 collaborators of Aung Naing. A scholar is included among the top collaborators of Aung Naing based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aung Naing. Aung Naing is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors breakdown → 2021 ·Clinical Cancer Research ·Giuseppe Curigliano, Hans Gelderblom, Nicolas Mach, Toshihiko Doi, David Tai, Patrick M. Forde, John Sarantopoulos, Philippe L. Bédard, Chia‐Chi Lin, F. Stephen Hodi, Sofie Wilgenhof, Armando Santoro, Catherine Sabatos-Peyton, Tyler A. Longmire, Alexandros Xyrafas, Haiying Sun, Sabine Gutzwiller, Luigi Manenti, Aung Naing	257
2	Safety and Clinical Activity of MEDI1873, a Novel GITR Agonist, in Advanced Solid Tumors 2020 ·Clinical Cancer Research ·Ani Sarkis Balmanoukian, Jeffrey R. Infante, Raid Aljumaily, Aung Naing, Ashish V. Chintakuntlawar, Naiyer A. Rizvi, Helen J. Ross, Michael S. Gordon, Philip R. Mallinder, Nairouz Elgeioushi, Ignacio Ferreira González, Nathan Standifer, Jennifer Cann, Nicholas M. Durham, (unknown), Rakesh Kumar, Crystal S. Denlinger	40
3	Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers 2018 ·Clinical Cancer Research ·Vivek Subbiah, Ravi Murthy, David S. Hong, Robert M. Prins, Chitra Hosing, (unknown), (unknown), (unknown), Robert G. Brown, Mary F. McGuire, (unknown), Sarina A. Piha‐Paul, Aung Naing, Anthony P. Conley, Robert S. Benjamin, Indreshpal Kaur, Marnix L. Bosch	29
4	Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act 2017 ·Clinical Cancer Research ·Kenneth L. Kehl, (unknown), Siqing Fu, Goldy C. George, Kenneth R. Hess, Filip Jankú, Daniel D. Karp, Shumei Kato, (unknown), Razelle Kurzrock, Aung Naing, Shubham Pant, Sarina A. Piha‐Paul, Vivek Subbiah, Apostolia M. Tsimberidou, David S. Hong	4
5	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells 2016 ·Clinical Cancer Research ·Chad Tang, James W. Welsh, Patricia M. de Groot, Erminia Massarelli, Joe Y. Chang, Kenneth R. Hess, Sreyashi Basu, Michael A. Curran, Maria E. Cabanillas, Vivek Subbiah, Siqing Fu, Apostolia M. Tsimberidou, Daniel D. Karp, Daniel R. Gomez, Adi Diab, Ritsuko Komaki, John V. Heymach, Padmanee Sharma, Aung Naing, David S. Hong	251
6	TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics 2016 ·Molecular Cancer Therapeutics ·Jennifer J. Wheler, Filip Jankú, Aung Naing, Yali Li, Bettzy Stephen, Ralph Zinner, Vivek Subbiah, Siqing Fu, Daniel D. Karp, Gerald S. Falchook, Apostolia M. Tsimberidou, Sarina A. Piha‐Paul, Roosevelt Anderson, (unknown), Vincent A. Miller, Roman Yelensky, J. Jack Lee, David S. Hong, Razelle Kurzrock	73
7	Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study 2016 ·Cancer Research ·Jennifer J. Wheler, Filip Jankú, Aung Naing, Yali Li, Bettzy Stephen, Ralph Zinner, Vivek Subbiah, Siqing Fu, Daniel D. Karp, Gerald S. Falchook, Apostolia M. Tsimberidou, Sarina A. Piha‐Paul, Roosevelt Anderson, (unknown), Vincent A. Miller, Roman Yelensky, J. Jack Lee, David S. Hong, Razelle Kurzrock	149
8	Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma 2015 ·Clinical Cancer Research ·David S. Hong, Razelle Kurzrock, Jennifer J. Wheler, Aung Naing, Gerald S. Falchook, Siqing Fu, Kevin B. Kim, Michael A. Davies, Ly M. Nguyen, Goldy C. George, Lucy T. Xu, Robert Shumaker, Min Ren, (unknown), Cynthia Bedell, Corina Andresen, Perminder S. Sachdev, James P. O'Brien, John Nemunaitis	57
9	Triple-Negative Breast Cancer Patients Treated at MD Anderson Cancer Center in Phase I Trials: Improved Outcomes with Combination Chemotherapy and Targeted Agents 2014 ·Molecular Cancer Therapeutics ·Prasanth Ganesan, Stacy L. Moulder, J. Jack Lee, Filip Jankú, Vicente Valero, Ralph Zinner, Aung Naing, Siqing Fu, Apostolia M. Tsimberidou, David S. Hong, Bettzy Stephen, Philip Stephens, Roman Yelensky, Funda Meric‐Bernstam, Razelle Kurzrock, Jennifer J. Wheler	29
10	Weekly nab -Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase I Trial 2013 ·Clinical Cancer Research ·Ana M. González-Angulo, Funda Meric‐Bernstam, Sant P. Chawla, Gerald S. Falchook, David S. Hong, Argun Akçakanat, Huiqin Chen, Aung Naing, Siqing Fu, Jennifer J. Wheler, Stacy Moulder, Thorunn Helgason, Shaoyi Li, Ileana Elias, Neil Desai, Razelle Kurzrock	63
11	Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations 2013 ·Molecular Cancer Therapeutics ·Prasanth Ganesan, Filip Jankú, Aung Naing, David S. Hong, Apostolia M. Tsimberidou, Gerald S. Falchook, Jennifer J. Wheler, Sarina A. Piha‐Paul, Siqing Fu, Vanda M. Stepanek, J. Jack Lee, Rajyalakshmi Luthra, Michael J. Overman, Scott Kopetz, Robert A. Wolff, Razelle Kurzrock	38
12	A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas 2012 ·Clinical Cancer Research ·David S. Hong, Razelle Kurzrock, Jeffrey G. Supko, Xiaoying He, Aung Naing, Jennifer J. Wheler, Donald P. Lawrence, Joseph P. Eder, Colin J. Meyer, Deborah A. Ferguson, James W. Mier, Marina Konopleva, Sergej Konoplev, Michael Andreeff, Donald Küfe, Hillard Lazarus, Geoffrey I. Shapiro, Bruce J. Dezube	197
13	Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative 2012 ·Clinical Cancer Research ·Apostolia M. Tsimberidou, Nancy G. Iskander, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Siqing Fu, Sarina A. Piha‐Paul, Aung Naing, Filip Jankú, Rajyalakshmi Luthra, Ye Yang, Sijin Wen, Donald A. Berry, Razelle Kurzrock	387
14	Survival of 1,181 Patients in a Phase I Clinic: The MD Anderson Clinical Center for Targeted Therapy Experience 2012 ·Clinical Cancer Research ·Jennifer J. Wheler, Apostolia M. Tsimberidou, David S. Hong, Aung Naing, Gerald S. Falchook, Sarina A. Piha‐Paul, Siqing Fu, Stacy L. Moulder, Bettzy Stephen, Sijin Wen, Razelle Kurzrock	77
15	Phase I Clinical Trial Outcomes in 93 Patients with Brain Metastases: The MD Anderson Cancer Center Experience 2011 ·Clinical Cancer Research ·Apostolia M. Tsimberidou, (unknown), Sijin Wen, Jennifer J. Wheler, David S. Hong, Aung Naing, Nancy G. Iskander, (unknown), Razelle Kurzrock	18
16	A Phase 1 Dose Escalation, Pharmacokinetic, and Pharmacodynamic Evaluation of eIF-4E Antisense Oligonucleotide LY2275796 in Patients with Advanced Cancer 2011 ·Clinical Cancer Research ·David S. Hong, Razelle Kurzrock, Yun Oh, Jennifer J. Wheler, Aung Naing, Les Brail, Sophie Callies, Valérie André, Sunil Kadam, Aejaz Nasir, Timothy R. Holzer, Funda Meric‐Bernstam, Mayer Fishman, George R. Simon	113
17	PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors 2011 ·Molecular Cancer Therapeutics ·Filip Jankú, Apostolia M. Tsimberidou, Ignacio Garrido‐Laguna, Xuemei Wang, Rajyalakshmi Luthra, David S. Hong, Aung Naing, Gerald S. Falchook, John W. Moroney, Sarina A. Piha‐Paul, Jennifer J. Wheler, Stacy Moulder, Siqing Fu, Razelle Kurzrock	289
18	Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center Experience 2011 ·The Oncologist ·Hazem El‐Osta, David S. Hong, Jennifer J. Wheler, Siqing Fu, Aung Naing, Gerald S. Falchook, Marshall E. Hicks, Sijin Wen, Apostolia M. Tsimberidou, Razelle Kurzrock	53
19	Patients with Advanced Head and Neck Cancers Have Similar Progression-Free Survival on Phase I Trials and Their Last Food and Drug Administration–Approved Treatment 2010 ·Clinical Cancer Research ·Ignacio Garrido‐Laguna, Filip Jankú, Gerald S. Falchook, Siqing Fu, David S. Hong, Aung Naing, (unknown), Xuemei Wang, Merrill S. Kies, Razelle Kurzrock	14
20	Phase I Clinical Trials in 56 Patients with Thyroid Cancer: The M. D. Anderson Cancer Center Experience 2009 ·The Journal of Clinical Endocrinology & Metabolism ·Apostolia M. Tsimberidou, Christos Vaklavas, Sijin Wen, David S. Hong, Jennifer J. Wheler, Chaan S. Ng, Aung Naing, (unknown), Naifa L. Busaidy, Maurie Markman, Steven I. Sherman, Razelle Kurzrock	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact